Latest From Alaric DeArment
In addition to securing a key position in first-line disease, Keytruda has potential to expand its presence in later lines with combination data from Seagen/Genmab’s Tivdak.
Adding oleclumab and monalizumab to the PD-L1 inhibitor improved PFS, while another study showed improved real-world outcomes.
Phase III sub-analyses presented at ESMO show the drug providing a survival benefit in a complex subpopulation, as well as improvements to quality of life.
An expert pointed out that XLMTM patients are already at high risk, but if linked to therapy toxicity, the death could doom the ASPIRO trial.
The partnership worth up to $1.75bn removes the significant risk of going it alone in a competitive market as Regenxbio awaits late-stage data for its gene therapy.
The Jennifer Doudna-backed startup got a billion-dollar valuation with VC rounds totaling $195m. CEO Trevor Martin talked with Scrip about Mammoth’s ultra-small CRISPR system technology.